Ryan Langston, an analyst from TD Cowen, maintained the Hold rating on DaVita (DVA – Research Report). The associated price target remains the same with $165.00.
Ryan Langston has given his Hold rating due to a combination of factors impacting DaVita’s financial outlook. The company’s EBIT estimates for FY25 and FY26 have been slightly adjusted downward, reflecting a shift in the timing of treatments and a modest impact from flu-related issues in the first quarter of 2025. Despite these adjustments, the price target remains steady at $165, indicating a cautious yet stable outlook.
Additionally, a recent cyber incident disclosed by DaVita adds an element of uncertainty to its operations. While patient care continues, the full extent and duration of the disruption are yet to be determined, potentially complicating the company’s performance in 2025. These factors collectively contribute to the Hold rating, suggesting that while there are challenges, the stock’s current valuation is appropriate given the circumstances.
In another report released on April 10, Barclays also maintained a Hold rating on the stock with a $169.00 price target.